Connect with us

Hi, what are you looking for?

Jewish Business News


Sealantis Alga-mimetic tissue adhesives Receives CE Mark for Seal-V

Sealantis Ltd., a private start-up,  from the Technion-Israel Institute of Technology that develops alga-mimetic tissue adhesives, reports that it has received the CE Mark for Seal-V, its vascular sealant. Seal-V  is a protein-free bioresorbable sealant, intended to achieve hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels such as the carotid, femoral, brachial and iliac arteries.

Seal-V commences a new generation in tissue sealing. Being alga-mimetic it has an intrinsic ability to bind strongly to both native blood vessels and synthetic grafts, even in wet and moist conditions. In addition, the protein-free composition relieves Seal-V  from risks associated with the use of protein-based products. Unlike hemostats, which are designed to cause blood to clot, Seal-V  is not dependent on the presence of blood in order to be effective, and can be used as a prophylactic sealant.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

“We are excited to be able to introduce Seal-V to the European market and to provide surgeons with a new and better option for controlling bleeding from suture-lines.” says Mr. Tomer Fuchs, Sealantis CEO. Mr. Fuchs recently joined Sealantis, after serving over two decades in lead executive positions in global companies including Medtronic Ventor, Anorad and Vishay.

Sealantis has been working closely with surgeons to leverage the extraordinary capabilities of its alga-mimetic technology and design products that will be strongly positioned in the multibillion dollars market of wound closure.” Says Dr. Zeev Gilkis, Sealantis Chairman.

In addition to Seal-V, Sealantis has a pipeline of advanced solutions for a variety of clinical needs. Among them is a gastro-intestinal sealant, designed to prevent leakage of intestinal content from anastomoses, a potentially fatal complication of GI surgery; an adhesive for space obliteration in esthetic surgeries, which can significantly reduce the recovery time from face and body lifts and innovative combination devices for site-specific drug delivery.

About Sealantis Ltd.

Sealantis Ltd. is developing a proprietary platform of alga-mimetic tissue adhesives, for a variety of applications and clinical needs in surgical leakage control, tissue adhesion and drug delivery. The Sealantis adhesives are protein-free, and have an extraordinary ability to adhere strongly to internal tissues even in wet environments. Sealantis was founded in 2007 by Prof. Havazelet Bianco-Peled from the Technion, and is funded by the Alfred Mann Institute at the Technion (AMIT)



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.